How does Dexycu work to treat inflammation associated with cataract surgery?

Dexycu contains dexamethasone, which is a corticosteroid that prevents the release of substances in the body that cause inflammation.

Dexycu (dexamethasone) from Icon Bioscience Inc., is an injectable, long-acting, corticosteroid intraocular suspension administered into the posterior (rear) chamber of the eye to lower inflammation (swelling) after cataract surgery. Dexycu is given as a single injection at the conclusion of surgery.

What is the advantage of Dexycu injection over eye drops?

Because Dexycu is given as a single, long-acting injection after cataract surgery, patients would not need to self-administer anti-inflammatory eye drops several times daily over a period of weeks after eye surgery. This may be especially advantageous in older patients, and lower the risk of non-compliance and dosing errors linked with frequent eye drops following cataract surgery. However, other eye drops, such as antibiotics, may be needed after cataract surgery.